Rankings
▼
Calendar
TARS Q4 2025 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
TARS
Tarsus Pharmaceuticals, Inc.
$3B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$152M
+128.4% YoY
Gross Profit
$141M
92.8% margin
Operating Income
-$8M
-5.3% margin
Net Income
-$8M
-5.5% margin
EPS (Diluted)
$-0.20
QoQ Revenue Growth
+27.8%
Cash Flow
Operating Cash Flow
$19M
Free Cash Flow
$13M
Stock-Based Comp.
$14M
Balance Sheet
Total Assets
$562M
Total Liabilities
$219M
Stockholders' Equity
$343M
Cash & Equivalents
$184M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$152M
$66M
+128.4%
Gross Profit
$141M
$61M
+128.9%
Operating Income
-$8M
-$24M
+67.3%
Net Income
-$8M
-$23M
+63.8%
Revenue Segments
Product
$152M
100%
← FY 2025
All Quarters